Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="602812.fig.002a" src="https://static.hindawi.com/articles/cherp/volume-2011/602812/figures/602812.fig.002a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Impact of adding BEV to overall survival</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="602812.fig.002b" src="https://static.hindawi.com/articles/cherp/volume-2011/602812/figures/602812.fig.002b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>Impact of adding BEV to survival after recurrence</td></tr></table></td></tr></table>

<table>BEV increases survival when administered to patients with recurrent GBM. (a) Overall survival. (b) Survival after recurrence. BEV (solid line), No-BEV (dotted line).</table>

Chemotherapy Research and Practice

fig2

Figure 2

Figure 2: Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma 